Literature DB >> 8428795

Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo.

S B Sobottka1, M R Berger, H Eibl.   

Abstract

This study was carried out to investigate whether structure-activity relationships of alkylphosphocholines, a new group of anti-neoplastic agents, which had been detected in methylnitrosourea(MNU)-induced rat mammary carcinoma, can be transferred to in vitro systems. Therefore, the anti-neoplastic activity of 4 alkylphosphocholines (APCs) was compared in 6 tumor cell lines in vitro and in MNU-induced rat mammary carcinoma in vivo. The in vitro system consisted of 2 rat mammary-carcinoma-derived cell lines (1/C2 and 1/C32), as well as 2 human mammary-gland (MDA-MB-231 and MCF-7)- and gastrointestinal tract (HT-29 and KB)-derived tumor cell lines. As assessed by both cell counting and MTT-assay, the ranking of concentrations effecting 50% growth inhibition (IC50) was parallel in all cell lines for octadecylphosphocholine (18:0-PC), octadecenyl-(trans-9.10)-phosphocholine (t-18:1-PC) and octadecenyl-(cis-9.10)-phosphocholine (c-18:1-PC). Only hexadecylphosphocholine (16:0-PC) differed in its activity, being least active in 1/C2, 1/C32 and MDA-MB-231 cells, moderately active in KB and MCF-7 cells, and most active in HT-29 cells. The IC50 concentrations of APCs in the 2 rat mammary carcinoma cell lines significantly correlated with dosages effecting a 50% tumor growth delay in vivo. Remarkably, the 2 gastrointestinal cell lines were more sensitive to APC exposure than the mammary-carcinoma cell lines. In all cell lines except KB cells, growth-stimulation effects were seen in the concentration range preceding the anti-proliferative activity; in vivo, however, no accelerated cancer growth was observed. The in vitro system failed to describe the superior therapeutic ratio of c-18:1-PC, as assessed in vivo, because it does not take the relative sensitivity of tumor vs. normal cells into account. Complementary in vivo trials are therefore indispensable for a final evaluation. Comparison of the 2 in vitro assays shows good agreement of the interrelationship of IC50 values, those obtained by MTT assay being on average 25% higher than those obtained from cell counting.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428795     DOI: 10.1002/ijc.2910530312

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.

Authors:  K Seifert; M Duchêne; W H Wernsdorfer; H Kollaritsch; O Scheiner; G Wiedermann; T Hottkowitz; H Eibl
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.

Authors:  Ilina K Dineva; Maya M Zaharieva; Spiro M Konstantinov; Hansjörg Eibl; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-30       Impact factor: 4.553

3.  Hexadecylphosphocholine differs from conventional cytostatic agents.

Authors:  M R Berger; B Betsch; M Gebelein; E Amtmann; P Heyl; H R Scherf
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.

Authors:  Michael Fiegl; Lars H Lindner; Matthias Juergens; Hansjoerg Eibl; Wolfgang Hiddemann; Jan Braess
Journal:  Cancer Chemother Pharmacol       Date:  2007-10-06       Impact factor: 3.333

5.  Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.

Authors:  I Fichtner; R Zeisig; H Naundorf; S Jungmann; D Arndt; G Asongwe; J A Double; M C Bibby
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.

Authors:  M Lohmeyer; P Workman
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.